Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101

Journal of Clinical Oncology - United States
doi 10.1200/jco.2010.29.7978
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab as Initial Therapy for Chronic Lymphocytic Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2005English

Profile of Obinutuzumab for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

OncoTargets and Therapy
OncologyPharmacology
2015English

A Phase I Study of Tipifarnib Combined With Conventional Induction and Consolidation Therapy for Previously Untreated Patients With Acute Myeloid Leukemia Aged 60 Years and Over

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2008English

A Breakthrough Therapy in Relapsed Chronic Lymphocytic Leukemia: The Combination of Idelalisib and Rituximab

Postdoc journal
2014English

Update on Therapy of Chronic Lymphocytic Leukemia

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Cost-Effectiveness of Adding Rituximab to Fludarabine and Cyclophosphamide for Treatment of Chronic Lymphocytic Leukemia in Ukraine

Cancer Management and Research
Oncology
2015English

Humoral Immune Responses Toward Tumor-Derived Antigens in Previously Untreated Patients With Chronic Lymphocytic Leukemia

Oncotarget
Oncology
2016English

Filgrastim and Alemtuzumab (Campath-1h) for Refractory Chronic Lymphocytic Leukemia

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2005English

Frontline Therapy for Chronic Lymphocytic Leukemia: The Dilemma Continues

Clinical Cancer Research
Cancer ResearchOncology
2008English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy